http://rdf.ncbi.nlm.nih.gov/pubchem/patent/MX-2018014279-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e6c6f4df9d92b667762a8445c73d4892
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-118
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2563-107
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6874
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-686
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6841
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-663
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2878
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68
filingDate 2017-05-25-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_68139838c2272747d171fdc1eda5eb5a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4a213ae96689cd72172fb4ef8fd81fd7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_09a58866df48adce8d27dcb7f18d0f17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_791056d04b72c30afd9f088f520fb941
publicationDate 2019-07-08-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber MX-2018014279-A
titleOfInvention THERAPEUTIC TREATMENT OF BREAST CANCER BASED ON C-MAF STATE.
abstract The present invention relates to the design of a personalized therapy for a subject with breast cancer based on the expression level of c-MAF and the subject's menopausal status. In some embodiments, personalized therapy comprises an agent to prevent or prevent bone degradation. In some embodiments, the agent to prevent or prevent bone breakdown is zoledronic acid.
priorityDate 2016-05-25-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID904836
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID884769
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID1027066
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID3625451
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID54267
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID37336
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID4094
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID17132
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCQ719N3
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID782481
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID3354925
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID936605
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID68740
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID29555082
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID114467
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419535486

Total number of triples: 48.